<DOC>
	<DOC>NCT02538016</DOC>
	<brief_summary>The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impact on urinary stone risk parameters, among adolescent and young adult patients with clinical cystinuria.</brief_summary>
	<brief_title>TCUPS- Tolvaptan Use in Cyctinuria and Urolithiasis: A Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Urolithiasis</mesh_term>
	<mesh_term>Cystinuria</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Males and females age 12 25 years Weight â‰¥ 25kg (55 lbs) Confirmed cystinuria diagnosis Specific blood test levels (done within the past 6 months) Concurrent nonrenal disease that might increase risk of complications due to aquaresis Liver or biliary disease (chronic or acute) Malabsorption syndrome or other gastrointestinal condition that may interfere with response to therapy Noncutaneous malignancy within last 5 years History of adverse reaction or allergy to Tolvaptan or other arginine vasopressin V2receptor antagonists</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cystinuria</keyword>
	<keyword>Kidney Stones</keyword>
</DOC>